Molecular structure of Rafoxanide, CAS Number: 22662-39-1
Rafoxanide (CAS 22662-39-1)
Alternate Names:
3′-Chloro-4′-(4-chlorophenoxy)-3,5-diiodosalicylanilide
Application:
Rafoxanide is an antiparasitic agent for research
CAS Number:
22662-39-1
Purity:
≥95%
Molecular Weight:
626.01
Molecular Formula:
C19H11Cl2I2NO3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Rafoxanide is a synthetic compound. The mechanism of action of rafoxanide involves inhibiting the synthesis of fumarate reductase, an essential enzyme in the metabolic processes of helminths. This inhibition results in a reduction of adenosine triphosphate (ATP) levels, which are vital for the survival and growth of helminths. By interfering with ATP production, rafoxanide impedes the energy supply necessary for the helminths continued existence.
Rafoxanide (CAS 22662-39-1) References
- Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. | El-Banna, HA., et al. 2008. Parasitol Res. 102: 1337-42. PMID: 18297309
- Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains. | AlAmri, MA., et al. 2017. ChemMedChem. 12: 639-645. PMID: 28371477
- Self-Association of Rafoxanide in Aqueous Media and Its Application in Preparing Amorphous Solid Dispersions. | Meng, F., et al. 2017. Mol Pharm. 14: 1790-1799. PMID: 28375620
- Study of Thermal Analysis Behavior of Fenbendazole and Rafoxanide. | Attia, AK., et al. 2017. Adv Pharm Bull. 7: 329-334. PMID: 28761836
- Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. | Shi, X., et al. 2018. Oncol Rep. 40: 1592-1600. PMID: 29956794
- Investigating the Association Mechanism between Rafoxanide and Povidone. | Meng, F., et al. 2018. Langmuir. 34: 13971-13978. PMID: 30360618
- Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway. | Xiao, W., et al. 2019. Cancer Lett. 444: 45-59. PMID: 30583070
- Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. | Laudisi, F., et al. 2019. Cancer Lett. 462: 1-11. PMID: 31351087
- Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by suppressing PI3K /Akt/mTOR pathway. | Liu, JZ., et al. 2019. Exp Cell Res. 385: 111691. PMID: 31678170
- Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways. | He, W., et al. 2020. Life Sci. 243: 117249. PMID: 31926247
- Repositioning rafoxanide to treat Gram-negative bacilli infections. | Miró-Canturri, A., et al. 2020. J Antimicrob Chemother. 75: 1895-1905. PMID: 32240294
- Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. | Di Grazia, A., et al. 2020. Cancers (Basel). 12: PMID: 32455811
- Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis. | Laudisi, F., et al. 2022. Biomed Pharmacother. 155: 113794. PMID: 36271571
- Discovery of rafoxanide as a novel agent for the treatment of non-small cell lung cancer. | Hu, A., et al. 2023. Sci Rep. 13: 693. PMID: 36639421
- Effect of early treatment with rafoxanide on antipyrine clearance in sheep infected with Fasciola hepatica. | Benchaoui, HA. and McKellar, QA. 1993. Xenobiotica. 23: 439-48. PMID: 8101676
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rafoxanide, 100 mg | sc-236665 | 100 mg | $82.00 |